Yunfeng Financial Group Limited

Comparability warning.

• FY2021–FY2022 are on HKFRS 4. FY2023 onward are on HKFRS 17, which moves investment components out of revenue and introduces the CSM.

• The five-year series below come from S&P Global Market Intelligence (via StockAnalysis), reconciled to company filings where possible.

• FY2024–FY2025 group profit, EPS and balance-sheet figures come from AR25-Ann and IR26.

• TipRanks shows different "total revenue" figures (FY2021 8,520; FY2022 2,610; FY2023 6,040; FY2024 4,870), reflecting a different aggregation. Net income figures agree across sources.

Income statement (5-year)

Sources:

• S&P/StockAnalysis for revenue, operating income and net income.

• Pre-tax income for FY2021–FY2024 from TipRanks (S&P data), consistent with S&P pretax margins. FY2025 is derived from the S&P pretax margin of 29.78%, applied to revenue of 4,187.

• EPS from AR25-Ann for FY2024–FY2025 and S&P for earlier years.

• Dividends: no final or interim dividend for FY2024, FY2025, 1H2025 or 1H2026 (AR25-Ann; IR26). FY2021–FY2023 are shown as 0 based on Marketlog's statement that the company does not pay dividends; individual-year verification is flagged as not confirmed.

Source: AR25-Ann.

Source: IR26 condensed income statement.

EBITDA. This is not a meaningful or disclosed metric for a life insurer. TipRanks shows aggregator EBITDA of 1,120 (FY2021), -246 (FY2022), 1,220 (FY2023) and 1,130 (FY2024), but these are not company-reported and are excluded from the analysis.

Margins and growth

A gross margin is not applicable to an insurer and is not shown.

Revenue CAGR (S&P basis):

• FY2021–FY2025: −20.6% a year, distorted by the HKFRS 4 to HKFRS 17 transition.

• FY2023–FY2025: +9.2% a year.

• Group insurance revenue FY2024 to FY2025: +9.9% (AR25-Ann).

• TPI FY2024 to FY2025: +32.7%.

Balance sheet

Sources: AR25-Ann; IR26 statement of financial position.

• They are placeholders for charting and are not values.

• S&P's definitions give total debt of 3,495 / 3,372 / 3,355 / 3,210 / 2,588 for FY2021–FY2025 and net cash of 519 / −848 / 592 / 1,141 / 2,704. These include leases and use a narrower definition of cash.

Short-term versus long-term debt split: not publicly disclosed in the materials reviewed. Maturities of the bank borrowings and the shareholder's loan were not itemised in AR25-Ann or IR26, and the shareholder lender is not named.

Working capital: not a meaningful concept for an insurer, and not disclosed.

Cash flow

Management guidance

No quantitative guidance. For the second half of 2026 management prioritises:

• product innovation, asset allocation, platform services and risk management;

• building the integrated traditional-plus-digital ecosystem;

• "sustainable long-term returns" (IR26).

Consensus

No sell-side consensus exists.

Bull case

1. Deep discount to intrinsic value. At about HK$2.0 the stock trades at 0.47x owner's EV equity (HK$4.27) and about 10x trailing earnings. This is despite FY2025 VNB of HK$1.55 billion and EV growth from HK$21.1 billion to HK$23.8 billion over 18 months. Even modest VNB, capitalised at a low multiple, implies material upside.

2. Earnings quality is improving. Net CSM release, insurance service result and investment result are all rising, the expense ratio has fallen to 6.4%, and solvency is above 200% with two A-range ratings. 1H2026 NPAT grew 30% even as new business paused.

3. Optionality at low cost. The digital-asset platform (VA licences, gold and FOF tokens, AlphaToken, WooshPay, Pharos, Ant links) is backed by HK$717 million of ring-fenced cash. Hong Kong's stablecoin and RWA regime could convert this into fee revenue without stressing the insurer.

Bear case

1. New business is rolling over. 1H2026 VNB fell 8%, APE grew 3% and the VNB margin compressed to about 24.6%. FY2025 may prove a cyclical CMV/broker peak, and a shrinking agency force limits organic resilience.

2. Governance discount is structural. The listco is controlled at 45% by Yu Feng, has had an interim CEO for two years, has disposed of YFML to a Yu Feng-linked buyer after intra-group write-offs, has related-party service frameworks, and pays no dividend. Minorities may keep capitalising earnings at a discount. In addition, 30% of YF Life's economics leak to co-investors.

3. Crypto pivot destroys value. Web3 spending (systems, talent, stakes) runs through a loss-making segment. FY2025 brought an HK$133 million investment loss and 1H2026 an HK$128 million intangible impairment, while ETH volatility adds noise. The September 2025 placing at HK$6.10 now looks opportunistic in hindsight.

Key catalysts and monitorables (next 12 months)

• Appointment of a permanent CEO.

• FY2026 results (expected around March 2027): VNB trajectory, VNB margin, CSM growth and dividend decision.

• Launch and traction of licensed VA trading and on-chain wealth products; deployment of the HK$717 million.

• ETH and digital-asset marks within the other financial services segment.

• Completion of the YFML disposal and any further related-party transactions.

• Any move on YF Life minority stakes or on MassMutual's 23.65% holding.

• IA statistics on CMV demand and any Mainland policy changes.

• Pillar Two effective tax rate.

• Fitch and Moody's reviews.

Analyst verdict

Yunfeng Financial is two companies under one ticker, and the market currently prices it as if the less valuable one dominates.

The first is YF Life. It is a mid-tier but well-capitalised and increasingly efficient Hong Kong and Macao life insurer. It roughly doubled new-business value in 2025, grew embedded value to HK$23.8 billion and net CSM to HK$10.0 billion, and holds A-range ratings from Fitch and Moody's. Its earnings engine (CSM release plus a 4.6–4.7% investment yield on a 97% investment-grade book) is predictable, and on its own it would justify a valuation well above today's roughly 0.47x owner's EV.

The second is the Web3 venture. It has real assets: SFC licence uplifts, live tokenised products, Ant-linked talent and strategic stakes. It also has no meaningful revenue (fee income of about HK$25 million per half-year), it is loss-making, and it was the catalyst for a speculative surge and a roughly 70% collapse in the share price.

What keeps the discount wide is governance rather than the insurer's fundamentals:

• a CEO seat filled on an interim basis since October 2024;

• no dividend despite HK$653 million of FY2025 profit;

• a controlled shareholder structure;

• related-party dealings such as the YFML disposal.

Our assessment is that the stock offers asymmetric value for patient investors who are comfortable with controlled-company risk. Downside is cushioned by insurance embedded value and holding-company net cash, while re-rating triggers are within management's control: a permanent CEO, a dividend or capital-return policy, and transparent reporting of digital-asset P&L.

Near-term new-business momentum is softening (1H2026 VNB −8%), so the case needs evidence that 2025 volumes were not a one-off. On balance we see the stock as undervalued, with high volatility and a governance overlay. We would monitor the FY2026 VNB print and any CEO appointment as the decisive signals before assigning higher conviction.